HRTX - Heron's Positive Data And Other News: The Good Bad And Ugly Of Biopharma
Heron Reports Positive Results From Mid-Stage Knee Replacement Trial
Heron Therapeutics (HRTX) announced that its Phase 2b clinical trial Study 209 has provided positive data with regard to HTX-011. The trial involved testing the drug candidate on patients undergoing total knee arthroplasty. The company stated that the HTX-011 met all primary and secondary endpoints of the study. The drug candidate also showed good tolerance and comparable safety profile.
Study 209 is a Phase 2b study and aimed to assess the potential of HTX-011 in primary unilateral total knee arthroplasty. The patients were given a single,